Alto Neuroscience (NYSE:ANRO) Upgraded at Zacks Research

Key Points

• Zacks Research upgraded Alto Neuroscience from “strong sell” to “hold,” while broader analyst sentiment remains “Moderate Buy,” with a consensus price target of $37.25.
• Alto Neuroscience shares opened at $34.36, up 0.3%, near their 52-week high of $35.41. The company reported a quarterly loss of $0.65 per share, beating estimates by $0.08.
• Several institutional investors recently established positions in the clinical-stage biotechnology company, which is developing biomarker-driven precision treatments for neuropsychiatric disorders.

Alto Neuroscience (NYSE:ANRO - Get Free Report) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research note issued to investors on Thursday,Zacks.com reports.

Other analysts also recently issued reports about the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. BTIG Research increased their target price on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a "buy" rating in a report on Thursday, August 13th. Chardan Capital restated a "buy" rating and set a $30.00 target price on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Robert W. Baird decreased their target price on shares of Alto Neuroscience from $38.00 to $36.00 and set an "outperform" rating for the company in a research report on Monday, May 18th. Finally, Wedbush lifted their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a "neutral" rating in a research note on Thursday, August 13th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $37.25.

Alto Neuroscience Stock Up 0.3%

ANRO stock opened at $34.36 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 14.85 and a quick ratio of 14.85. The stock has a market capitalization of $1.35 billion, a P/E ratio of -14.20 and a beta of 1.06. Alto Neuroscience has a fifty-two week low of $3.41 and a fifty-two week high of $35.41. The business has a 50-day moving average of $27.36 and a 200-day moving average of $23.39.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.08. On average, sell-side analysts anticipate that Alto Neuroscience will post -2.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently made changes to their positions in ANRO. Torren Management LLC acquired a new stake in shares of Alto Neuroscience in the 4th quarter valued at approximately $62,000. GK Wealth Management LLC acquired a new position in Alto Neuroscience during the second quarter worth $226,000. Balyasny Asset Management L.P. acquired a new position in Alto Neuroscience during the fourth quarter worth $198,000. OMERS ADMINISTRATION Corp bought a new stake in Alto Neuroscience during the fourth quarter worth $221,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Alto Neuroscience during the fourth quarter worth $304,000.

About Alto Neuroscience

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source